Genmab is a world leader in the development of antibody-based therapeutics. Bionomics' partnership with Genmab was originally initiated in March 2002 as a research and development collaboration for the discovery of novel angiogenesis targets. This partnership was highly successful and led to the identification of over 150 novel genes that have potential as targets for the treatment of cancer.

In February 2006, the companies restructured the agreement such that Genmab will assume all future responsibility for development of eight angiogenesis targets in exchange for upfront fees, milestone payments and royalties to be paid to Bionomics.

For more information about Genmab, visit